Şunu aradınız:: peri procedural (İngilizce - Maltaca)

procedural
edima

procedural fees
Ħlasijiet proċedurali

procedural requirements
rekwiŻiti proĊedurali

procedural compliance,
ir-rispett lejn il-proċeduri,

procedural complication:
komplikazzjoni ta’ xi proċedura:

agriculture in peri-urban
l-agrikoltura

peri-operative pain management.
għall-maniġġjar ta’ l-uġigħ fiż-żmien tal-operazzjoni.

agriculture in peri-urban areas
l-agrikultura f’ żoni peri-urbani

peri- and postnatal development has not been studied.
Żvilupp waqt u wara t-twelid ma ġiex studjat.

peri- and postnatal development studies were not conducted.
ma sarux studji ta 'l- iżvilupp madwar u wara l- ħlas.

peri- and post-natal toxicity has not been investigated.
tossiċità ta’ waqt u wara t-twelid ma ġietx investigata.

reproduction, peri- and postnatal development studies were conducted in rats.
studji ta’ riproduzzjoni, u ta’ zvilupp madwar u wara t-twelid saru f’firien.

no peri/post-natal developmental toxicity studies have been performed.
ma twettqux studji dwar l-effett tossiku fl-iżvilupp matul u wara t-twelid.

in a 30-day study (accoast) in 4033 patients with nstemi with elevated troponin who were scheduled for coronary angiography followed by pci within 2 to 48 hours after randomization, subjects who received prasugrel 30 mg loading dose on average 4 hours prior to coronary angiography followed by a 30 mg loading dose at the time of pci (n=2037) had an increased risk of non-cabg peri-procedural bleeding and no additional benefit compared to patients receiving a 60 mg loading dose at the time of pci (n=1996).
f’studju li dam 30 ġurnata (accoast),f’4033 pazjent b’nstemi u b’livell għoli ta’ troponin li kellhom ippjanata anġjografija koronarja segwita minn pci fi żmien sagħtejn sa 48 siegħa minn meta ntagħżlu b’mod arbitrarju, il-pazjenti li ngħataw doża ta’ kkargar ta’ 30 mg prasugrel, b’medja ta’ 4 sigħat qabel l-anġjografija koronarja segwita minn doża ta’ kkargar ta’ 30 mg fil-ħin tal- pci (n=2037) kellhom żieda fir-riskju ta’ fsada non-cabg peri-proċedurali u ebda benefiċċju addizzjonali meta mqabbla ma’ pazjenti li ngħataw doża ta’ kkargar ta’ 60 mg fil-ħin tal-pci (n=1996).